TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02353455

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
Study: NCT01836198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study: NCT00678977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
Study: NCT05082623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music medicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Earplug
Description: Earplug with noise cancelling
Study: NCT01667172

Intervention type: DEVICE
Group type: OTHER
Intervention: Point-of-Care C Reactive Protein measurement on capillary blood
Description: capillary blood fingerstick method to determine C Reactive Protein level in the blood
Study: NCT04300153

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP Block
Description: At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
Study: NCT04300153

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Global Quality of Recovery-15 score
Description: Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Quality of Recovery-15 score
Description: Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
Study: NCT03715387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Topical 0.1% Topical Ointment
Description: Topical tacrolimus ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polysporin Ointment
Description: Polysporin ointment
Study: NCT04205487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Study: NCT05490823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A smartphone app for anemia screening
Description: This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
Study: NCT00741585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any antihypertensive medication alone or in combination
Description: All drugs on awakening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any antihypertensive medication alone or in combination
Description: One or more drugs at bedtime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
Study: NCT03252197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UGIJVC with needle guide device
Description: Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UGIJVC without needle guide device
Description: participants who are tested performance for ultrasound guided cannulation using conventional method.
Study: NCT02897180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nyaditum resae(R)
Description: Capsules containing Nyaditum resae(R)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containin Placebo
Study: NCT04554342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V01 candy
Description: candy with sweetener (Isomalt) and apple flavour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V02 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V03 candy
Description: candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
Study: NCT04554342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V04 candy
Description: candy with sweetener (Isomalt) (control group 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V05 candy
Description: candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
Study: NCT04467710

Intervention type: PROCEDURE
Intervention: Laparoscopic common bile duct exploration.
Description: Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time.

Intervention type: PROCEDURE
Intervention: Laparoscopic common bile duct exploration.
Description: Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time.
Study: NCT03232164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET
Description: 18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
Study: NCT03414905

Intervention type: DEVICE
Intervention: Aspira Catheter
Description: * 15.5Fr catheter~* Standard of care
Study: NCT01903369

Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: Shear wave elastography
Study: NCT03414905

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Standard of care
Study: NCT00431067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT01762449

Intervention type: OTHER
Intervention: Followup survey

Intervention type: OTHER
Intervention: Followup survey
Study: NCT02102100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menthol
Description: In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menthol
Description: In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
Study: NCT02798354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: 1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: 1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Collaborative
Description: 1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
Study: NCT04302740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LEAP
Description: The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
Study: NCT03626324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2P
Description: The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
Study: NCT03545646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with High Intensity Focused ElectroMagnetic system
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study: NCT04128891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Cardiomagnetic Resonance Imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril-Valsartan
Description: Cardiomagnetic Resonance Imaging
Study: NCT01860144

Intervention type: DRUG
Intervention: Bevacizumab
Study: NCT01835028

Intervention type: OTHER
Intervention: Echocardiography
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Echocardiography
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Computed tomography
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Computed tomography
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Blood biomarkers
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Blood biomarkers
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Stress echocardiography
Description: Observational Study using Imaging and Biomarkers

Intervention type: OTHER
Intervention: Stress echocardiography
Description: Observational Study using Imaging and Biomarkers